Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Leukemia stem cells (LSCs) are found in most aggressive myeloid diseases and contribute to therapeutic resistance. Leukemia cells exhibit a dysregulated developmental program as the result of genetic and epigenetic alterations. Overexpression of the RNA-binding protein Musashi2 (MSI2) has been previously shown to predict poor survival in leukemia. Here, we demonstrated that conditional deletion of Msi2 in the hematopoietic compartment results in delayed leukemogenesis, reduced disease burden, and a loss of LSC function in a murine leukemia model. Gene expression profiling of these Msi2-deficient animals revealed a loss of the hematopoietic/leukemic stem cell self-renewal program and an increase in the differentiation program. In acute myeloid leukemia patients, the presence of a gene signature that was similar to that observed in Msi2-deficent murine LSCs correlated with improved survival. We determined that MSI2 directly maintains the mixed-lineage leukemia (MLL) self-renewal program by interacting with and retaining efficient translation of Hoxa9, Myc, and Ikzf2 mRNAs. Moreover, depletion of MLL target Ikzf2 in LSCs reduced colony formation, decreased proliferation, and increased apoptosis. Our data provide evidence that MSI2 controls efficient translation of the oncogenic LSC self-renewal program and suggest MSI2 as a potential therapeutic target for myeloid leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 1×
“…the RNA-seq gene signature corresponding to 177 genes from our LSCs in which Msi2 was deleted (human homologs and >6 mean log intensity; Supplemental Table 3) with the gene expression obtained from patients in the Eastern Cooperative Oncology Group E1900 trial (363 patients; GEO GSE24505) (41, 42).”
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · cited 1×
“A dysregulated developmental epigenetic program is considered to be a general feature of many cancers, and mutations or chromosomal translocations with histone methyltransferases contribute to transformation in myeloid leukemias (1, 2).”
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 4×
“Among these pathways, we identified that MSI2’s direct RNA targets were associated with the MLL-AF9 self-renewal signature that is shared between leukemic granulocyte monocyte progenitors (GMPs) and HSCs (29).”
InfluentialThe translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313 · cited 2×
“Furthermore, mTOR pathway activation in cancer results in altered translation that can be clinically targeted with the addition of inhibitors such as rapalogs (25).”
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs
Oskarsson, T., Acharyya, S., Zhang, X. H.-F., Vanharanta, S., Tavazoie, S. F., Morris, P. G., Downey, R. J., Manova-Todorova, K., Brogi, E., & Massagué, J. (2011) · Nature Medicine · doi:10.1038/nm.2379 · Cited by 869 · cited 2×
“Genetic and functional studies show that expression of MSI1 is upregulated in pediatric brain tumors and metastatic breast cancer and knockdown of MSI1 reduces the proliferation of different solid tumor cell lines (8–10).”
The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia
Draptchinskaia, N., Gustavsson, P., Andersson, B., Pettersson, M., Willig, T.-N., Dianzani, I., Ball, S., Tchernia, G., Klar, J., Matsson, H., et al. (1999) · Nature Genetics · doi:10.1038/5951 · Cited by 795
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
Epigenetic reprogramming in cancer
Suvà, M. L., Riggi, N., & Bernstein, B. E. (2013) · Science · doi:10.1126/science.1230184 · Cited by 706 · cited 1×
“org Volume 125 Number 3 March 2015 Introduction A dysregulated developmental epigenetic program is considered to be a general feature of many cancers, and mutations or chromosomal translocations with histone methyltransferases contribute to transformation in myeloid leukemias (1, 2).”
Cited by
RNA-Binding Proteins in Cancer: Old Players and New Actors
Pereira, B., Billaud, M., & Almeida, R. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.05.003 · Cited by 773
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Cancer epigenetics: Moving forward
Nebbioso, A., Tambaro, F. P., Dell’Aversana, C., & Altucci, L. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007362 · Cited by 480
New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.27 · Cited by 378
Erratum: New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.30 · Cited by 303
Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets
Kudinov, A. E., Karanicolas, J., Golemis, E. A., & Boumber, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2728 · Cited by 262
HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis
Sun, Y., Zhou, B., Mao, F., Xu, J., Miao, H., Zou, Z., Phuc Khoa, L. T., Jang, Y., Cai, S., Witkin, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.018 · Cited by 152
Self-citationIKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation
Park, S.-M., Cho, H., Thornton, A. M., Barlowe, T. S., Chou, T., Chhangawala, S., Fairchild, L., Taggart, J., Chow, A., Schurer, A., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.10.016 · Cited by 97
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript regulated gene in Msi2-deficient LSCs and the high expression of IKZF2 and MSI2 in LSCs suggested that these factors can coordinate to maintain the LSC program.”
BackgroundResultInfluentialSelf-citation
Metadata
- Authors
- Park, S.-M., Gönen, M., Vu, L., Minuesa, G., Tivnan, P., Barlowe, T. S., Taggart, J., Lu, Y., Deering, R. P., Hacohen, N., Figueroa, M. E., Paietta, E., Fernandez, H. F., Tallman, M. S., Melnick, A., Levine, R., Leslie, C., Lengner, C. J., & Kharas, M. G.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-02-09
- Volume
- 125
- Issue
- 3
- Pages
- 1286-1298
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2061347183
- Cited by
- 110
- References
- 17
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.